Cancer remains one of the world’s leading causes of death, affecting millions of people and their families every year.
Although doctors now have many ways to treat cancer, including surgery, chemotherapy, radiation, and immunotherapy, many patients still have limited treatment options.
One of the biggest challenges is that some modern treatments depend heavily on the body’s immune system. If a person’s immune system is weak, these therapies often do not work as well.
This problem is particularly important for people whose immune systems have been damaged by chemotherapy, advanced cancer, aging, or other health conditions. For these patients, finding a treatment that can attack cancer without relying on the immune system could make a major difference.
A team of researchers in Japan has now developed a promising new approach called AUN therapy. The study was led by Professor Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST).
He worked together with scientists from Daiichi Sankyo Co., Ltd. and the University of Tsukuba. Their findings were published in the journal Nature Biomedical Engineering.
The idea of using bacteria to fight cancer is actually more than 150 years old. In the late 1800s, a German doctor named Wilhelm Busch noticed that one of his cancer patients improved after developing a bacterial infection.
Later, in 1893, American surgeon Dr. William Coley intentionally used bacteria to treat cancer patients. His work became one of the earliest forms of cancer immunotherapy.
Over the years, scientists have continued to build on these early observations. Today’s advanced immunotherapies, including checkpoint inhibitors and CAR-T cell therapy, can achieve remarkable results in some patients.
However, these treatments still depend on the immune system being able to recognize and destroy cancer cells. Unfortunately, not every patient has an immune system strong enough to respond effectively.
AUN therapy takes a completely different approach. Instead of depending on immune cells, it uses two natural types of bacteria that work together as a team to attack cancer directly.
The first bacterium is called Proteus mirabilis, which the researchers named A-gyo. The second is Rhodopseudomonas palustris, which they named UN-gyo. According to the researchers, these two bacteria have different but complementary roles.
A-gyo is naturally attracted to tumors. Once it enters the tumor environment, it changes its shape and becomes much more effective at attacking cancer cells. It serves as the main cancer-killing force in the treatment.
UN-gyo has a different role. It is a photosynthetic bacterium that helps regulate and support the activity of A-gyo. It helps improve the treatment while also reducing harmful effects that might occur if A-gyo became too aggressive. In this way, the two bacteria balance each other.
At the beginning of treatment, the bacterial mixture contains mostly UN-gyo. However, once the bacteria enter the tumor, the balance gradually changes.
A-gyo becomes the dominant bacterium inside the tumor and begins attacking the cancer cells more aggressively. This natural shift allows the treatment to adapt to conditions inside the tumor and become more effective at destroying cancer.
One of the most encouraging findings is that AUN therapy appears to produce relatively few side effects. In particular, it avoids a dangerous complication called cytokine release syndrome.
This condition can occur during some forms of immunotherapy and can cause severe inflammation throughout the body. Avoiding this problem could make the new treatment safer for many patients.
The name AUN comes from a Japanese cultural idea that represents balance and harmony between opposite forces. The concept is often symbolized by two guardian figures, one with an open mouth and one with a closed mouth.
In this new cancer treatment, the name reflects how the two bacteria work together in perfect balance. One bacterium attacks the tumor, while the other controls and supports the process.
The researchers believe this balance is one of the reasons why the treatment may succeed where other therapies fail. By using a living system that can respond to the tumor environment and regulate itself, AUN therapy may provide a smarter and more targeted way of fighting cancer.
Professor Miyako and his colleagues are now planning the next stage of development. They hope to launch a startup company to advance the technology and begin human clinical trials within the next six years.
Although much more research is needed before the treatment can be used in hospitals, the findings are highly promising. AUN therapy represents a new generation of bacterial cancer treatments that do not rely on the immune system. It also demonstrates how scientists can take inspiration from natural biological systems to develop innovative medical therapies.
If future studies confirm its safety and effectiveness in humans, AUN therapy could become an important option for cancer patients who currently have very few choices. For many people living with cancer, especially those with weakened immune systems, this new approach offers a much-needed source of hope for the future.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and vitamin D supplements could strongly reduce cancer death.
For more information about health, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing higher intake of dairy foods linked to higher prostate cancer risk.
Copyright © 2026 Knowridge Science Report. All rights reserved.
